A small pilot trial in 18 dogs with HER2+ appendicular OSA revealed that ADXS31-164 administered following standard of care (SOC) amputation and adjuvant carboplatin, safely induced HER2-specific IFN- responses, delayed metastases, and increased disease free interval (DFI) and overall survivial (OS) when compared to a historical control group of dogs with HER2+appendicular OSA [39]. Here, IFNA1 is linked to obstructive sleep apnea syndrome.